Navigation Links
Leading Researchers in Vision Impairment and Blindness to Present at EURETINA Winter Meeting
Date:2/1/2013

e useful vision in patients blinded by RP and is implanted below the retina in the macular region. Published in Proceedings of the Royal Society B in 2010, results from the Company's first human clinical trial showed that placement of the implant below the retina provided optimum visual results, allowing patients to recognize foreign objects, as well as recognize letters to form words. Beginning in May 2010, the Company's second human clinical trial is currently underway in Germany, the UK and Hong Kong.

Sister company Okuvision GmbH's OkuStim® technology received CE mark approval in 2011 for use as a treatment to help delay the progression of RP. The device consists of a frame worn on the patient's head and a hand-held stimulation controller that works by sending small amounts of current to stimulate the retina. Results of Okuvision's pilot study were published in April 2011 in Investigative Ophthalmology and Visual Science  and showed that patients receiving 150 percent stimulation showed a 20 percent statistically significant improvement in their field of vision. The Company recently launched two additional, post-market studies in Germany and other European countries to continue research on the OkuStim device.

"Last year was a pivotal time for Okuvision, with the launch of two post-market studies on our OkuStim device and the beginning of patient enrolment throughout the EU and UK," said Reinhard Rubow , CEO, Okuvision GmbH. "With more information expected
'/>"/>

SOURCE Retina Implant AG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Leading Cardiologist Dispels the Myths about Dietary Supplement Niacin
2. DenMat Announces Signing a Purchase Agreement to Acquire PeriOptix Inc., Leading Provider of Magnification and Illumination Technologies
3. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
4. World Diagnostic Imaging Market Outlook and Leading Suppliers Business Strategies and Marketing Tactics
5. Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
6. Optimal Radiology Partners with Leading Radiology Practice
7. Frost & Sullivan Solidifies the Prominence of Leading Organizations through Best Practice Recognition
8. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
9. 90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
10. LABSCO Implements Leading-Edge Technology to Support Growth and Seize Opportunities in the Clinical Laboratory Market
11. Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Calif. and BRUSSELS ... AMGN ) and UCB (Euronext Brussels: UCB) today ... evaluating effect of RomosozUmab Compared with Teriparatide in ... fracture pReviously treated with bisphosphonatE therapy). The study ... significant difference in favor of romosozumab in the ...
(Date:9/1/2015)... Sept. 1, 2015 Emerus Holdings, a ... emergent, inpatient and diagnostic care in partnership with ... a definitive agreement to receive a strategic investment ... a leading health care investment firm. ... patient-centric acute episodic and ambulatory clinical services to ...
(Date:9/1/2015)... IRVINE, Calif. , Sept. 1, 2015  Edwards ... in the science of heart valves and hemodynamic monitoring, ... Fargo Healthcare Conference at the Hyatt Regency Boston in ... 9, 2015. Michael A. Mussallem , ... keynote lunch speaker followed by a company discussion with ...
Breaking Medicine Technology:Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 2Emerus Announces Significant Strategic Investment By Welsh, Carson, Anderson & Stowe 3
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (NASDAQ: ... emerging leader in the development, assembly, marketing and sale ... that the Company,s growing business earned a BBB+ Credit Rating ... "Zhongguancun Association") and was approved as a member of ...
... SHANGHAI, Feb. 28, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... China-based pharmaceutical and biotechnology research and development outsourcing company, ... results for the fourth quarter and full year ended ... host a conference call to discuss the results at ...
Cached Medicine Technology:Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 2Dehaier Medical Awarded Strong Credit Rating From Beijing Zhongguancun Enterprises Credit Promotion Association 3ShangPharma to Report Fourth Quarter and Full Year 2011 Financial Results on March 13, 2012 2
(Date:9/1/2015)... ... September 01, 2015 , ... Consumers overwhelmingly prefer to have ... Surgery, according to a new survey that also offers insight on why that ... – which reflects views on cosmetic medical treatments and ratings for 10 specific ...
(Date:9/1/2015)... ... September 01, 2015 , ... Negative pressure ... inside a wound to remove exudates, fluid, and infectious materials to prepare the ... stand-alone devices, disposable devices, and canisters, etc.) is projected to expand continuously through ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... top-five hospital by U.S. News & World Report, to provide breaking news and ... Editorial and marketing groups within OncLive, which provides oncologists resources and information?they need ...
(Date:9/1/2015)... ... September 01, 2015 , ... PetPace, the provider ... vital signs and activity, today announced its integration with leading veterinary Practice Management ... widely-adopted veterinary hospital Practice Management Software packages in the US. Practice Management Software ...
(Date:9/1/2015)... ... September 01, 2015 , ... ... of version 5.2 of the FirstSpirit Content Management System with new capabilities and ... new version of FirstSpirit, companies will be well on their way to achieving ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 2Health News:World Negative Pressure Wound Therapy Market Assessed by GlobalData in In-demand Report Published at MarketPublishers.com 3Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 2Health News:OncLive® and Cleveland Clinic Team up to Provide News, Information About Cancer Research and Patient Care 3Health News:Petpace-Cornerstone Integration Lowers Overhead, Raises Data Visibility for Veterinary Practices 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3
... working in the radiological department is a grave problem. ... the Department of Diagnostic Radiology // at the University ... new technique to help doctors. He has developed a ... allow them to perform their routine job at the ...
... health service is losing more than ?50m because of people ... of similar complaint by NHS managers the situation is now ... Huntingdon said: ‘Some people do not turn up as they ... a lot of problems in lost capacity and extra work.’ ...
... has shown that cutting back a few calories from our ... certain age related changes in cells. // ... found that eating a little less food and exercising a ... aging-related cell and organ damage in rats. ...
... examining Budhia Singh has suggested that he goes ‘slow’ and ... sometime//. ,A warrant-cum-authorization letter from the Khurda district welfare ... hospital. ,The medical panel headed by the ... boy’s serum urea, potassium and ALKP (alkaline phosphatase) levels to ...
... the doses given to children differ greatly from that ... much is enough for children//. A pair of studies ... dosage a computerized affair could greatly help children and ... calculator and a computerized drug ordering system, developed under ...
... cannot go to school because their parents fear that sending ... states a World Bank report. ,"The net primary enrolment ... 45 percent. As the girls transit to middle school, there ... few girls go on to complete middle school and very, ...
Cached Medicine News:Health News:Cut Calories to Age Gracefully 2Health News:Cut Calories to Age Gracefully 3Health News:Budhia's Medical Report Fails to Address Long Term Health Issues 2Health News:Dispensing Drug Dosage To Children Through Computers 2Health News:Dispensing Drug Dosage To Children Through Computers 3Health News:Dispensing Drug Dosage To Children Through Computers 4Health News:‘Family Honour’ Hinder Pakistani Girls In Getting Educati 2
Reptilase-Time from Bothrops atrox...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Pefakit TAFI Calibrators and Controls...
Plasma Control Level 2 - 1 ml...
Medicine Products: